A new product will now provide U.S. veterinarians with an alternative to treat joint dysfunction in horses associated with equine osteoarthritis.
NexHA is a low molecular weight, purified hyaluronate sodium formulation that can be administered by I.V. or I.A. injection. It is approved by the Food and Drug Administration (FDA) for the treatment of joint dysfunction of the carpus or fetlock in horses that is caused by non-infectious synovitis or osteoarthritis.
Hyaluronic Acid (HA) is a natural and essential component of articular cartilage and synovial fluid in horses. In joints affected by synovitis or osteoarthritis, the presence of HA is reduced.
NexHA is available in a 4ml (40 mg) vial for an intravenous injection. It is a clear, colorless, sterile, and preservative-free solution of low viscosity.
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, and Athens, Georgia, and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Armidale, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located. Visit www.bionicheanimalhealth.com for more information.
